These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38253342)

  • 21. Lipoprotein(a) and cardiovascular disease.
    Boffa MB; Koschinsky ML
    Biochem J; 2024 Oct; 481(19):1277-1296. PubMed ID: 39302109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions.
    Kotani K; Serban MC; Penson P; Lippi G; Banach M
    Crit Rev Clin Lab Sci; 2016 Dec; 53(6):370-8. PubMed ID: 27173621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
    Puri R; Nissen SE; Arsenault BJ; St John J; Riesmeyer JS; Ruotolo G; McErlean E; Menon V; Cho L; Wolski K; Lincoff AM; Nicholls SJ
    JAMA Cardiol; 2020 Oct; 5(10):1136-1143. PubMed ID: 32639518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK; Vallejo-Vaz AJ; Ginsberg HN; Davidson MH; Louie MJ; Bujas-Bobanovic M; Minini P; Eckel RH; Cannon CP
    Atherosclerosis; 2019 Sep; 288():194-202. PubMed ID: 31253441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HEART UK consensus statement on Lipoprotein(a): A call to action.
    Cegla J; Neely RDG; France M; Ferns G; Byrne CD; Halcox J; Datta D; Capps N; Shoulders C; Qureshi N; Rees A; Main L; Cramb R; Viljoen A; Payne J; Soran H;
    Atherosclerosis; 2019 Dec; 291():62-70. PubMed ID: 31704552
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.
    Ma GS; Chiou TT; Wilkinson MJ
    Curr Cardiol Rep; 2023 Oct; 25(10):1175-1187. PubMed ID: 37632608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon.
    Bucci M; Tana C; Giamberardino MA; Cipollone F
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):980-986. PubMed ID: 27514608
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
    Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
    Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies.
    Cesaro A; Schiavo A; Moscarella E; Coletta S; Conte M; Gragnano F; Fimiani F; Monda E; Caiazza M; Limongelli G; D'Erasmo L; Riccio C; Arca M; Calabrò P
    J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):151-161. PubMed ID: 32858625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated lipoprotein(a) levels: A crucial determinant of cardiovascular disease risk and target for emerging therapies.
    Afzal Z; Cao H; Chaudhary M; Chigurupati HD; Neppala S; Alruwaili W; Awad M; Sandesara D; Siddique M; Farman A; Zafrullah F; Gonuguntla K; Sattar Y
    Curr Probl Cardiol; 2024 Aug; 49(8):102586. PubMed ID: 38653440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target.
    Di Fusco SA; Arca M; Scicchitano P; Alonzo A; Perone F; Gulizia MM; Gabrielli D; Oliva F; Imperoli G; Colivicchi F
    Heart; 2022 Dec; 109(1):18-25. PubMed ID: 35288443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipoprotein (a): When to Measure and How to Treat?
    Rhainds D; Brodeur MR; Tardif JC
    Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a): Are we ready for large-scale clinical trials?
    Zheng S; Fang G; Du J; Dong J
    Int J Cardiol; 2024 Sep; 410():132236. PubMed ID: 38848771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice.
    Delgado-Lista J; Mostaza JM; Arrobas-Velilla T; Blanco-Vaca F; Masana L; Pedro-Botet J; Perez-Martinez P; Civeira F; Cuende-Melero JI; Gomez-Barrado JJ; Lahoz C; Pintó X; Suarez-Tembra M; Lopez-Miranda J; Guijarro C
    Clin Investig Arterioscler; 2024; 36(4):243-266. PubMed ID: 38599943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein(a) and Cardiovascular Diseases　- Revisited.
    Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
    Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a)-60 Years Later-What Do We Know?
    Pasławska A; Tomasik PJ
    Cells; 2023 Oct; 12(20):. PubMed ID: 37887316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein(a) as a Risk Factor for Cardiovascular Diseases: Pathophysiology and Treatment Perspectives.
    Vinci P; Di Girolamo FG; Panizon E; Tosoni LM; Cerrato C; Pellicori F; Altamura N; Pirulli A; Zaccari M; Biasinutto C; Roni C; Fiotti N; Schincariol P; Mangogna A; Biolo G
    Int J Environ Res Public Health; 2023 Sep; 20(18):. PubMed ID: 37754581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The re-emergence of lipoprotein(a) in a broader clinical arena.
    Tsimikas S
    Prog Cardiovasc Dis; 2016; 59(2):135-144. PubMed ID: 27497506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.